Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. (Q49687144)

21 February 2018

title

Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. (English)

1 reference

21 February 2018

1 reference

1

1 reference

21 February 2018

Christopher Gerner

2

1 reference

21 February 2018

Walter Berger

3

1 reference

21 February 2018

Christian Hartinger

4

1 reference

21 February 2018

Bernhard K. Keppler

5

1 reference

21 February 2018

publication date

24 November 2017

1 reference

21 February 2018

published in

Chemical Society Reviews

1 reference

21 February 2018

volume

47

1 reference

21 February 2018

issue

3

1 reference

21 February 2018

page(s)

909-928

1 reference

21 February 2018

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Platinum Compounds: a New Class of Potent Antitumour Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Cisplatin (cis-diamminedichloroplatinum II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Metal drugs become targeted.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis(imidazol)ruthenate(III)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Effects of cis -Dichlorodiammineplatinum (II) and Related Transition Metal Complexes on Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Inhibition of Topoisomerase II Catalytic Activity by Two Ruthenium Compounds: A Ligand-Dependent Mode of Action†

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Bioorganometallic chemistry--from teaching paradigms to medicinal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Inhibition of cancer cell growth by ruthenium(II) arene complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic ruthenium(II) arene compounds with antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Site selectivity of platinum anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2]

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Arene ruthenium complexes as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Targeted and multifunctional arene ruthenium chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Next-generation metal anticancer complexes: multitargeting via redox modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Development of anticancer agents: wizardry with osmium

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Metal-based anticancer chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Approaches to the design of catalytic metallodrugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Ruthenium half-sandwich complexes bound to protein kinase Pim-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

The contrasting chemical reactivity of potent isoelectronic iminopyridine and azopyridine osmium(ii) arene anticancer complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Bridging solubility between drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Catalytic organometallic anticancer complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Designing organometallic compounds for catalysis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA = 1,3,5-triaza-7-phosphaadamantane).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Organometallic osmium arene complexes with potent cancer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Global proteome analysis of the NCI-60 cell line panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Anticancer Gold(III) Porphyrins Target Mitochondrial Chaperone Hsp60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Identification of metal-associated proteins in cells by using continuous-flow gel electrophoresis and inductively coupled plasma mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Auranofin: repurposing an old drug for a golden new age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

Lectin-Gd-loaded chitosan hydrogel nanoparticles: a new biospecific contrast agent for MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC7CS00332C

21 January 2018

Identifiers

DOI

10.1039/C7CS00332C

1 reference

21 February 2018

PubMed ID

29170783

1 reference

21 February 2018